RESUMO
Considering the correlation between olfactory function and size of the human olfactory bulb (OB), it may be that OB volume is representative of the average number of functional olfactory receptor neurons in the nose. We observed a woman (64-year-old) with a 3-week history of hyposmia following an upper respiratory tract infection. Interestingly, both OB volumes were below the tenth percentile of the general population which seems to be difficult to explain by rapid, adaptive changes in the OB volume. It is hypothesized that small OBs may be a risk factor for acquiring olfactory loss.
Assuntos
Transtornos do Olfato/etiologia , Bulbo Olfatório/anatomia & histologia , Infecções Respiratórias/complicações , Feminino , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Nariz/fisiopatologia , Bulbo Olfatório/patologia , Fatores de RiscoRESUMO
PURPOSE: This study investigates the performance of a 3 D Ultrasound (US) system in imaging elbow and wrist nerves. MATERIALS AND METHODS: Twenty healthy volunteers with asymptomatic median, ulnar and radial nerves were prospectively investigated. Bilateral 3DUS scans of the elbows and wrists were acquired by using a commercially available US scanner (18 MHz, AplioXG, Toshiba) and stored as a 3 D volume by a dedicated software (CURE, Robarts Research Institute). Retrospectively, qualitative (image quality, atypical nerve location, findings potentially associated with compression neuropathy) and quantitative (cross-sectional area measurements) evaluations were performed. RESULTS: In all 200 nerves 3DUS was feasible (100%). Image quality was insufficient in 13.5% (25 ulnar nerve elbow, 2 radial nerve) and sonomorphology was not assessable in those nerves. Measurement of cross sectional areas was feasible in all nerves (100%). Median cross-sectional area (range) were: median nerve elbow 7 mm2 (6-9), radial nerve 3 mm2 (1-4), ulnar nerve elbow 8 mm2 (5-11), median nerve wrist 8 mm2 (5-10), and ulnar nerve wrist 4 mm2 (2-6). No significant changes in nerve cross-sectional area along each nerve was found. Ulnar nerve subluxation was found in 2 nerves (6.7%). No anconeus epitrochlearis muscle or osteophytes were found. CONCLUSION: 3DUS is a feasible method for assessing nerves of the upper extremity and has been shown to provide a good overview of the median, ulnar and radial nerve at the elbow and wrist, but is limited for evaluation of the ulnar nerve in the cubital tunnel. This technique enables reliable measurements at different locations along the nerve.
Assuntos
Braço/inervação , Interpretação de Imagem Assistida por Computador/métodos , Imageamento Tridimensional/métodos , Nervo Mediano/diagnóstico por imagem , Nervo Radial/diagnóstico por imagem , Nervo Ulnar/diagnóstico por imagem , Ultrassonografia/métodos , Cotovelo/diagnóstico por imagem , Cotovelo/inervação , Estudos de Viabilidade , Humanos , Posicionamento do Paciente , Valores de Referência , Sensibilidade e Especificidade , Punho/diagnóstico por imagem , Punho/inervaçãoRESUMO
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. The standard therapy for GBM is maximal surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide (TMZ). In spite of the extensive treatment, the disease is associated with poor clinical outcome. Further intensification of the standard treatment is limited by the infiltrating growth of the GBM in normal brain areas, the expected neurological toxicities with radiation doses >60 Gy and the dose-limiting toxicities induced by systemic therapy. To improve the outcome of patients with GBM, alternative treatment modalities which add low or no additional toxicities to the standard treatment are needed. Many Phase II trials on new chemotherapeutics or targeted drugs have indicated potential efficacy but failed to improve the overall or progression-free survival in Phase III clinical trials. In this review, we will discuss contemporary issues related to recent technical developments and new metabolic strategies for patients with GBM including MR (spectroscopy) imaging, (amino acid) positron emission tomography (PET), amino acid PET, surgery, radiogenomics, particle therapy, radioimmunotherapy and diets.